Exosome Research Market

Exosome Research Market by Product & Service (Kits, Reagents (Antibodies, Isolation Purification), Instruments), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem cell) - Global Forecast to 2028

Report Code: BT 6939 Jan, 2024, by marketsandmarkets.com

The global exosome research market in terms of revenue was estimated to be worth $169 million in 2023 and is poised to reach $356 million by 2028, growing at a CAGR of 16.0% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of the market is largely driven by the growing investments in biomedical research, both from the public and private sectors, which provide substantial financial support for exosome-related studies. Research grants, collaborations, and funding initiatives further propel advancements in understanding exosome functions and applications.

Exosome Research Market- Global Forecast to 2028

Exosome Research Market

To know about the assumptions considered for the study, Request for Free Sample Report

Attractive Opportunities In The Exosome Research Market

Exosome Research Market

Global Exosome Research Market Dynamics

DRIVER: Rising cancer prevalence

As the prevalence of cancer diseases continues to rise, there is a growing demand for innovative therapies to address them. This surge in demand has put exosome based technologies at the forefront of cancer research and treatment. The concept of liquid biopsy, which involves analyzing biomarkers in bodily fluids such as blood, urine, or saliva, is gaining prominence in cancer diagnostics. Exosomes, being stable carriers of molecular information, are ideal candidates for liquid biopsy approaches. Researchers are exploring the use of exosomal biomarkers for monitoring disease progression, treatment response, and detecting minimal residual disease.

RESTRAINT: Technical complexity of exosome isolation and technological limitations

Exosomes exhibit heterogeneity in terms of size, composition, and cargo. The technical challenge lies in isolating exosomes with high purity and specificity, distinguishing them from other extracellular vesicles and contaminants present in biological samples. The lack of standardized isolation methods can lead to variability in experimental outcomes and hinder comparability between studies. Further, the isolation of exosomes from biological samples can be technically demanding due to the presence of other extracellular vesicles and contaminants. Achieving pure and high-yield exosome isolation requires sophisticated techniques, and variations in isolation methods can affect the quality and consistency of obtained exosome samples.

OPPORTUNITY: Increasing demand for personalized medicine

The rising demand for precision medicine presents a significant opportunity for exosome research due to the unique characteristics of exosomes and their potential applications in tailoring medical treatments to individual patients.  Exosomes are implicated in the development of drug resistance in various diseases. Studying the content and function of exosomes shed by resistant cells can contribute to the identification of mechanisms underlying resistance. This information is crucial for devising personalized treatment strategies that overcome or circumvent resistance.

CHALLENGE: Limited understanding of cargo loading

The limited understanding of cargo loading into exosomes is a notable challenge in exosome research. The cargo loading process involves the selective packaging of specific biomolecules, such as proteins, nucleic acids, and lipids, into exosomes. The mechanisms that govern the selective loading of cargo into exosomes are not fully understood. It is unclear how certain molecules are preferentially sorted and enriched within exosomes, while others are excluded. Elucidating the selective packaging mechanisms is crucial for manipulating cargo content and optimizing exosomes for therapeutic applications. Strategies to engineer exosomes for specific cargo loading profiles require a deeper understanding of the underlying biological mechanisms.

Global Exosome Research Market Ecosystem Analysis

The ecosystem of exosome research consists of end users from pharmaceutical & biotechnology companies, academic & research institutes, and hospital & clinical laboratories.  Exosome research product and service providers, reagent & kits suppliers, technology providers, data management & analysis providers, regulatory authorities (ensuring compliance and safety), and collaborative networks promoting knowledge sharing and collaboration. These stakeholders interact and collaborate to drive the advancement of base editing products and services, enhance drug discovery processes, and develop new therapeutics.

Exosome Research Market Ecosystem

Note: this report also provides market sizing and forecast for Exosomes Manufacturing services for end products as an additional separate chapter at global level.

Reagents & Kits held a dominant share in the product & service segment in the exosome research industry.

By products & services, the exosome research market has been categorized in reagents & kits, instruments, and services. The kits and reagents segment is further categorized as antibodies, isolation, purification, quantitation kits & reagents, and other kits & reagents. In 2022, reagents & kits accounted for the largest share of the market. Kits and reagents are designed to be scalable, accommodating varying sample sizes and experimental needs. This scalability makes them suitable for both small-scale studies in academic research and large-scale applications in pharmaceutical and biotechnology industries.

The academic & research institute segment of exosome research industry is expected to register the fastest growth during the forecast period.

Based on the end user, the exosome research market has been segmented into academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & clinical testing laboratories. In 2022, academic & research institutes accounted for the largest share. This can be attributed to the fact that exosomes hold immense potential in diagnostics and therapeutics, including drug delivery and regenerative medicine. The enthusiasm surrounding these potential applications has fueled increased research efforts within academic and research institutions. Researchers are exploring exosomes as biomarkers for various diseases and as vehicles for targeted drug delivery, leading to a surge in research initiatives.

North America accounted for the largest share in Exosome research industry in 2022.

Exosome Research Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Geographically, the exosome research market is segmented into North America, Europe, Asia Pacific, and Rest of World. North America held the dominant share followed by Europe. North America has a well-established infrastructure for funding research and development initiatives, providing financial support to companies working on exosome research. Moreover, the regulatory environment in North America is often supportive of innovation in the life sciences sector.

Key players in the global Exosome research market include Thermo Fisher Scientific, Inc. (US), Bio-Techne (US), System Biosciences, LLC (US), QIAGEN (Germany), Lonza (Switzerland), NX Pharmagen (US), NanoSomiX (US), Miltenyi Biotech (Germany), Norgen Biotek Corp. (Canada), AMSBio (UK), Aethlon Medical, Inc. (US), Anjarium Biosciences AG (UK), Ciloa (France), InnovaPrep LLC (US), Creative Medical Technologies Holdings, Inc. (US), ILIAS Biologics, Inc. (South Korea), Unchained Labs (US), Rion, Inc. (US), Cell Guidance System, LLC (UK), INOVIQ (Australia), Danaher Corporation (US), Exopharm (Australia), Everzom (France), RoosterBio, Inc. (US), and Creative Biolabs (US).

Scope of the Exosome Research Industry

Report Metric

Details

Market Revenue in 2023

$169 million

Projected Revenue by 2028

$356 million

Revenue Rate

Poised to Grow at a CAGR of 16.0%

Market Driver

Rising cancer prevalence

Market Opportunity

Increasing demand for personalized medicine

This report categorizes the exosome research market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

  • Kits & Reagents
    • Antibodies
    • Isolation, Purification, Quantitation Kits, and reagents
    • Other kits & reagents
  • Instruments
  • Services

By Indication

  • Cancer Indication
    • Lung Cancer
    • Breast Cancer
    • Prostate Cancer
    • Colorectal Cancer
    • Other Cancers
  • Neurodegenerative Diseases
  • Cardiovascular Diseases
  • Infectious Diseases
  • Other Diseases

By Application

  • Biomarkers
  • Vaccine Development
  • Tissue Regeneration
  • Other applications

By Manufacturing Service

  • Stem cell-derived exosome manufacturing services
  • Dendritic cell-derived exosome manufacturing services
  • Other manufacturing services

By End User

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Clinical Laboratories

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • Japan
    • China
    • Rest of Asia Pacific (RoAPAC)
  • Rest of World

Recent Developments of Exosome Research Industry

  • In February 2022, Bio-Techne entered an exclusive agreement with Thermo Fisher Scientific to develop and commercialize the ExoTRU kidney transplant rejection test designed by Bio-Techne. This liquid biopsy test offers allograft health information suitable for clinical and research applications.
  • In November 2020, Lonza acquired an exosome manufacturing facility from Codiak BioSciences. The latter retained its pipeline of therapeutic candidates and exosome drug-loading technologies while receiving manufacturing services from Lonza.
  • In September 2020, The entities extended their non-exclusive partnership to co-market exosome technology. Their existing customers include biopharma partners and the joint development of new exosome-based products. This granted QIAGEN a non-exclusive development license to exosome technology (manufactured by Bio-Techne) to develop companion in vitro diagnostic products (CDX-IVD).

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 32)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKETS COVERED 
           1.3.1 MARKET SCOPE
           1.3.2 YEARS CONSIDERED
           1.3.3 CURRENCY CONSIDERED
    1.4 STAKEHOLDERS 
    1.5 SUMMARY OF CHANGES 
           1.5.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 36)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 BREAKDOWN OF PRIMARIES: EXOSOME RESEARCH MARKET
    2.2 MARKET ESTIMATION METHODOLOGY 
          FIGURE 3 EXOSOME RESEARCH INDUSTRY SIZE ESTIMATION  (SUPPLY-SIDE ANALYSIS), 2022
          FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
                    FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
    2.3 MARKET GROWTH RATE PROJECTIONS 
          FIGURE 6 MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
          FIGURE 7 MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS
           2.3.1 DATA TRIANGULATION
                    FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.4 LIMITATIONS 
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 RECESSION IMPACT 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)
          TABLE 2 US: HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US: HEALTH EXPENDITURE, 2023–2030 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 47)
    FIGURE 9 EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE,  2023 VS. 2028 (USD MILLION)
    FIGURE 10 EXOSOME RESEARCH INDUSTRY, BY INDICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 MARKET, BY APPLICATION,  2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 MARKET: GEOGRAPHICAL SNAPSHOT
 
4 PREMIUM INSIGHTS (Page No. - 51)
    4.1 EXOSOME RESEARCH MARKET OVERVIEW 
          FIGURE 14 RISING INVESTMENTS IN PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH
    4.2 EXOSOME RESEARCH INDUSTRY: BY MANUFACTURING SERVICE 
          FIGURE 15 STEM CELL-DERIVED EXOSOME MANUFACTURING SERVICES TO HOLD LARGEST MARKET SHARE TILL 2028
    4.3 ASIA PACIFIC: MARKET SHARE,  BY APPLICATION & COUNTRY (2022) 
          FIGURE 16 BIOMARKERS ACCOUNTED FOR LARGEST SHARE OF APPLICATION  SEGMENT IN 2022
    4.4 MARKET FOR CANCER, BY TYPE,  2023 VS. 2028 (USD MILLION) 
          FIGURE 17 LUNG CANCER SEGMENT CONTINUES TO DOMINATE MARKET IN 2028
    4.5 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 18 NORTH AMERICA AND EUROPE MARKETS TO SHOW HIGHER GROWTH
    4.6 MARKET SHARE, BY END USER, 2022 
          FIGURE 19 ACADEMIC & RESEARCH INSTITUTES TO DOMINATE MARKET DURING  FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 56)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 20 EXOSOME RESEARCH MARKET: DRIVERS, RESTRAINTS,  OPPORTUNITIES, AND CHALLENGES
          TABLE 4 EXOSOME RESEARCH INDUSTRY: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Increasing investment in pharmaceutical and life sciences research
                    5.2.1.2 Rising cancer prevalence
                                TABLE 5 GLOBAL CANCER INCIDENCE, 2022 VS. 2025
                    5.2.1.3 Increasing interest in exosome-based procedures
           5.2.2 RESTRAINTS
                    5.2.2.1 Technical complexity of exosome isolation and technological limitations
                    5.2.2.2 Regulatory uncertainty in exosome research
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Rising investments in emerging countries for exosome research
                    5.2.3.2 Growing interest in exosome-based therapeutics
                    5.2.3.3 Increasing demand for personalized medicine
           5.2.4 CHALLENGES
                    5.2.4.1 Lack of gold standard protocols for exosome development and production
                    5.2.4.2 Limited understanding of cargo loading
    5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 21 REVENUE SHIFT AND NEW POCKETS FOR EXOSOME PROVIDERS
    5.4 PRICING ANALYSIS 
          TABLE 6 AVERAGE SELLING PRICES OF KEY PLAYERS, BY PRODUCT
          TABLE 7 REGIONAL VARIATIONS IN PRODUCT COSTS
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 22 VALUE CHAIN ANALYSIS OF EXOSOME RESEARCH: R&D AND MANUFACTURING PHASES ADD MAXIMUM VALUE
    5.6 SUPPLY CHAIN ANALYSIS 
          FIGURE 23 MARKET: SUPPLY CHAIN ANALYSIS
    5.7 ECOSYSTEM/MARKET MAP 
          FIGURE 24 MARKET ECOSYSTEM
          TABLE 8 MARKET: ROLE IN ECOSYSTEM
    5.8 TECHNOLOGY ANALYSIS 
          TABLE 9 MARKET: TECHNOLOGY ANALYSIS—EXOSOME ISOLATION
          TABLE 10 MARKET: TECHNOLOGY ANALYSIS—EXOSOME CHARACTERIZATION
          TABLE 11 MARKET: TECHNOLOGY ANALYSIS—EXOSOME ANALYSIS
    5.9 PATENT ANALYSIS 
          FIGURE 25 PATENT APPLICATIONS FOR MARKET, JANUARY 2013–OCTOBER 2023
          TABLE 12 INDICATIVE LIST OF PATENTS IN MARKET
    5.10 KEY CONFERENCES AND EVENTS, 2024–2025 
           TABLE 13 MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
    5.11 REGULATORY ANALYSIS 
           5.11.1 NORTH AMERICA
                    5.11.1.1 US
                    5.11.1.2 Canada
           5.11.2 EUROPE
                    5.11.2.1 Germany
                    5.11.2.2 France
                    5.11.2.3 UK
           5.11.3 ASIA PACIFIC
                    5.11.3.1 China
                    5.11.3.2 Japan
                    5.11.3.3 India
           5.11.4 REST OF THE WORLD
                    5.11.4.1 Brazil
                    5.11.4.2 Argentina
                    5.11.4.3 Saudi Arabia
           5.11.5 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.12 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 18 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.12.1 THREAT OF NEW ENTRANTS
           5.12.2 THREAT OF SUBSTITUTES
           5.12.3 BARGAINING POWER OF SUPPLIERS
           5.12.4 BARGAINING POWER OF BUYERS
           5.12.5 INTENSITY OF COMPETITIVE RIVALRY
    5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EXOSOME PRODUCTS & SERVICES
           5.13.2 BUYING CRITERIA FOR EXOSOME PRODUCTS & SERVICES
                     FIGURE 27 KEY BUYING CRITERIA FOR END USERS
 
6 EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE (Page No. - 84)
    6.1 INTRODUCTION 
          TABLE 19 EXOSOME RESEARCH INDUSTRY, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
    6.2 KITS & REAGENTS 
          TABLE 20 EXOSOME RESEARCH KITS & REAGENTS MARKET, BY REGION,  2021–2028 (USD MILLION)
          TABLE 21 NORTH AMERICA: EXOSOME RESEARCH KITS & REAGENTS MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 22 EUROPE: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 23 ASIA PACIFIC: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 24 EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
           6.2.1 ANTIBODIES
                    6.2.1.1 High demand for exosome-based markers for disease detection to propel growth
                                TABLE 25 EXOSOME RESEARCH ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 26 NORTH AMERICA: EXOSOME RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 27 EUROPE: EXOSOME RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 28 ASIA PACIFIC: EXOSOME RESEARCH ANTIBODIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
           6.2.2 ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS
                    6.2.2.1 Availability of rapid and easy-to-use kits & reagents to ensure sustained demand
                                TABLE 29 EXOSOME RESEARCH ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 30 NORTH AMERICA: EXOSOME RESEARCH ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 31 EUROPE: EXOSOME RESEARCH ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 32 ASIA PACIFIC: EXOSOME RESEARCH ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.3 OTHER KITS & REAGENTS
                    TABLE 33 OTHER EXOSOME RESEARCH KITS & REAGENTS MARKET, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 34 NORTH AMERICA: OTHER EXOSOME RESEARCH KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 35 EUROPE: OTHER EXOSOME RESEARCH KITS & REAGENTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 36 ASIA PACIFIC: OTHER EXOSOME RESEARCH KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 INSTRUMENTS 
           6.3.1 DEMAND FOR SCALABLE EXOSOME DEVELOPMENT VIA HIGH-THROUGHPUT SYSTEMS TO DRIVE GROWTH
                    TABLE 37 EXOSOME RESEARCH INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 38 NORTH AMERICA: EXOSOME RESEARCH INSTRUMENTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 39 EUROPE: EXOSOME RESEARCH INSTRUMENTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 40 ASIA PACIFIC: EXOSOME RESEARCH INSTRUMENTS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
    6.4 SERVICES 
           6.4.1 LACK OF IN-HOUSE RESOURCES TO SUPPORT GROWTH OF SERVICES SECTOR
                    TABLE 41 EXOSOME RESEARCH SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 42 NORTH AMERICA: EXOSOME RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 43 EUROPE: EXOSOME RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 44 ASIA PACIFIC: EXOSOME RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
 
7 EXOSOME RESEARCH MARKET, BY INDICATION (Page No. - 97)
    7.1 INTRODUCTION 
          TABLE 45 EXOSOME RESEARCH INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
    7.2 CANCER 
          TABLE 46 EXOSOME RESEARCH INDUSTRY FOR CANCER, BY REGION, 2021–2028 (USD MILLION)
          TABLE 47 NORTH AMERICA: MARKET FOR CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 48 EUROPE: MARKET FOR CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 49 ASIA PACIFIC: MARKET FOR CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 50 MARKET FOR CANCER, BY TYPE, 2021–2028 (USD MILLION)
           7.2.1 LUNG CANCER
                    7.2.1.1 Increasing prevalence and advancements in instruments and assays for liquid biopsy to drive market
                                TABLE 51 EXOSOME RESEARCH INDUSTRY FOR LUNG CANCER, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 52 NORTH AMERICA: MARKET FOR LUNG CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 53 EUROPE: MARKET FOR LUNG CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 54 ASIA PACIFIC: MARKET FOR LUNG CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
           7.2.2 BREAST CANCER
                    7.2.2.1 High prevalence and increasing awareness to drive market
                                TABLE 55 EXOSOME RESEARCH INDUSTRY FOR BREAST CANCER, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 56 NORTH AMERICA: MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 57 EUROPE: MARKET FOR BREAST CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 58 ASIA PACIFIC: MARKET FOR BREAST CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
           7.2.3 PROSTATE CANCER
                    7.2.3.1 Effectiveness of liquid biopsy in detecting prostate cancer before surgery to support market growth
                                TABLE 59 EXOSOME RESEARCH INDUSTRY FOR PROSTATE CANCER, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 60 NORTH AMERICA: MARKET FOR PROSTATE CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 61 EUROPE: MARKET FOR PROSTATE CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 62 ASIA PACIFIC: MARKET FOR PROSTATE CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
           7.2.4 COLORECTAL CANCER
                    7.2.4.1 Increasing exosome-based research and projects to propel market
                                TABLE 63 EXOSOME RESEARCH INDUSTRY FOR COLORECTAL CANCER, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 64 NORTH AMERICA: MARKET FOR COLORECTAL CANCER,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 65 EUROPE: MARKET FOR COLORECTAL CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 66 ASIA PACIFIC: MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
           7.2.5 OTHER CANCERS
                    TABLE 67 EXOSOME RESEARCH INDUSTRY FOR OTHER CANCERS, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 68 NORTH AMERICA: MARKET FOR OTHER CANCERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 69 EUROPE: MARKET FOR OTHER CANCERS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 70 ASIA PACIFIC: MARKET FOR OTHER CANCERS, BY COUNTRY,  2021–2028 (USD MILLION)
    7.3 NEURODEGENERATIVE DISEASES 
           7.3.1 POTENTIAL APPLICATIONS OF SALIVARY EXOSOMAL CARGO CONTENT IN TREATMENT TO DRIVE MARKET
                    TABLE 71 EXOSOME RESEARCH INDUSTRY FOR NEURODEGENERATIVE DISEASES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 72 NORTH AMERICA: MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 73 EUROPE: MARKET FOR NEURODEGENERATIVE DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 74 ASIA PACIFIC: MARKET FOR NEURODEGENERATIVE DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
    7.4 CARDIOVASCULAR DISEASES 
           7.4.1 EXPANDING RESEARCH ON CVD APPLICATIONS TO PROPEL SEGMENT GROWTH
                    TABLE 75 EXOSOME RESEARCH INDUSTRY FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 76 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 77 EUROPE: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 78 ASIA PACIFIC: MARKET FOR CARDIOVASCULAR DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
    7.5 INFECTIOUS DISEASES 
           7.5.1 POTENTIAL FOR DEEPER UNDERSTANDING OF INFECTIOUS DISEASE THERAPEUTICS TO DRIVE MARKET
                    TABLE 79 EXOSOME RESEARCH INDUSTRYFOR INFECTIOUS DISEASES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 80 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 81 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 82 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
    7.6 OTHER INDICATIONS 
          TABLE 83 EXOSOME RESEARCH INDUSTRY FOR OTHER INDICATIONS, BY REGION,  2021–2028 (USD MILLION)
          TABLE 84 NORTH AMERICA: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 85 EUROPE: MARKET FOR OTHER INDICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 86 ASIA PACIFIC: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
 
8 EXOSOME RESEARCH MARKET, BY APPLICATION (Page No. - 118)
    8.1 INTRODUCTION 
          TABLE 87 EXOSOME RESEARCH INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
    8.2 BIOMARKERS 
           8.2.1 BIOMARKERS TO HOLD LARGEST SHARE OF APPLICATIONS MARKET
                    TABLE 88 MARKET FOR BIOMARKERS, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 89 NORTH AMERICA: MARKET FOR BIOMARKERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 90 EUROPE: MARKET FOR BIOMARKERS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 91 ASIA PACIFIC: MARKET FOR BIOMARKERS, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 VACCINE DEVELOPMENT 
           8.3.1 GROWING INTEREST IN EXOSOMES IN INFECTIOUS DISEASE THERAPEUTICS TO DRIVE MARKET
                    TABLE 92 MARKET FOR VACCINE DEVELOPMENT, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 93 NORTH AMERICA: MARKET FOR VACCINE DEVELOPMENT,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 94 EUROPE: MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 95 ASIA PACIFIC: MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
    8.4 TISSUE REGENERATION 
           8.4.1 MINIMAL SIDE EFFECTS AND HIGH EFFICACY OF EXOSOMES TO SUPPORT ADOPTION
                    TABLE 96 MARKET FOR TISSUE REGENERATION, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 97 NORTH AMERICA: MARKET FOR TISSUE REGENERATION,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 98 EUROPE: MARKET FOR TISSUE REGENERATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 99 ASIA PACIFIC: MARKET FOR TISSUE REGENERATION, BY COUNTRY, 2021–2028 (USD MILLION)
    8.5 OTHER APPLICATIONS 
          TABLE 100 MARKET FOR OTHER APPLICATIONS, BY REGION,  2021–2028 (USD MILLION)
          TABLE 101 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS,  BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 102 EUROPE: MARKET FOR OTHER APPLICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 103 ASIA PACIFIC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 EXOSOME RESEARCH MARKET, BY END USER (Page No. - 127)
    9.1 INTRODUCTION 
          TABLE 104 EXOSOME RESEARCH INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
    9.2 ACADEMIC & RESEARCH INSTITUTES 
           9.2.1 ACADEMIC & RESEARCH INSTITUTES TO HOLD LARGEST SHARE OF END-USER MARKET
                    TABLE 105 MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 106 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 107 EUROPE: MARKET FOR ACADEMIC & RESEARCH INSTITUTES,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 108 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
           9.3.1 SIGNIFICANT DEVELOPMENTS IN NANOMEDICINE TO DRIVE MARKET
                    TABLE 109 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 110 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 111 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 112 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.4 HOSPITALS & CLINICAL TESTING LABORATORIES 
           9.4.1 RISING ADOPTION OF EXOSOME-BASED ONCOLOGY RESEARCH SOLUTIONS TO DRIVE MARKET
                    TABLE 113 MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES,  BY REGION, 2021–2028 (USD MILLION)
                    TABLE 114 NORTH AMERICA: MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 115 EUROPE: MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 116 ASIA PACIFIC: MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
 
10 EXOSOME RESEARCH MARKET, BY MANUFACTURING SERVICE (Page No. - 134)
     10.1 INTRODUCTION 
             TABLE 117 EXOSOME RESEARCH INDUSTRY, BY MANUFACTURING SERVICE,  2021–2028 (USD MILLION)
     10.2 STEM CELL-DERIVED EXOSOME MANUFACTURING 
             10.2.1 RISING DEMAND FOR MSC EXOSOMES IN THERAPEUTICS TO DRIVE MARKET
     10.3 DENDRITIC CELL-DERIVED EXOSOME MANUFACTURING 
             10.3.1 SIGNIFICANT DEVELOPMENTS IN DC-EXOSOME IMMUNOTHERAPY TO PROPEL GROWTH
     10.4 OTHER EXOSOME MANUFACTURING SERVICES 
 
11 EXOSOME RESEARCH MARKET, BY REGION (Page No. - 137)
     11.1 INTRODUCTION 
             TABLE 118 EXOSOME RESEARCH INDUSTRY, KEYWORD ANALYSIS (2001-2022)
             TABLE 119 MARKET, BY REGION, 2021–2028 (USD MILLION)
     11.2 NORTH AMERICA 
             FIGURE 28 NORTH AMERICA: EXOSOME RESEARCH MARKET SNAPSHOT
             TABLE 120 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
             TABLE 121 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
             TABLE 122 NORTH AMERICA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE,  2021–2028 (USD MILLION)
             TABLE 123 NORTH AMERICA: MARKET, BY INDICATION,  2021–2028 (USD MILLION)
             TABLE 124 NORTH AMERICA: MARKET FOR CANCER, BY TYPE,  2021–2028 (USD MILLION)
             TABLE 125 NORTH AMERICA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
             TABLE 126 NORTH AMERICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             11.2.1 US
                        11.2.1.1 HIGH BURDEN OF CANCER AND FAVORABLE PUBLIC & PRIVATE FUNDING FOR RESEARCH TO DRIVE MARKET
                                      TABLE 127 US: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 128 US: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 129 US: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 130 US: MARKET FOR CANCER, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 131 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 132 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 INCREASING FUNDING FOR GENOME-BASED MEDICAL TREATMENTS TO SUPPORT MARKET GROWTH
                                      TABLE 133 CANADA: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 134 CANADA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 135 CANADA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 136 CANADA: MARKET FOR CANCER, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 137 CANADA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 138 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.3 NORTH AMERICA: RECESSION IMPACT
     11.3 EUROPE 
             FIGURE 29 EUROPE: EXOSOME RESEARCH MARKET SNAPSHOT
             TABLE 139 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 140 EUROPE: MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
             TABLE 141 EUROPE: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE,  2021–2028 (USD MILLION)
             TABLE 142 EUROPE: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
             TABLE 143 EUROPE: MARKET FOR CANCER, BY TYPE,  2021–2028 (USD MILLION)
             TABLE 144 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 145 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Germany to dominate European market
                                      TABLE 146 GERMANY: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 147 GERMANY: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 148 GERMANY: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 149 GERMANY: MARKET FOR CANCER, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 150 GERMANY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 151 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.2 UK
                        11.3.2.1 Growing life sciences industry to drive market
                                      TABLE 152 UK: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 153 UK: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 154 UK: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 155 UK: MARKET FOR CANCER, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 156 UK: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 157 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.3 FRANCE
                        11.3.3.1 Strong collaborative network between biotechnology entities and research institutes to support growth
                                      TABLE 158 FRANCE: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 159 FRANCE: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 160 FRANCE: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 161 FRANCE: MARKET FOR CANCER, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 162 FRANCE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 163 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.4 REST OF EUROPE
                        TABLE 164 REST OF EUROPE: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                        TABLE 165 REST OF EUROPE: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 166 REST OF EUROPE: MARKET, BY INDICATION,  2021–2028 (USD MILLION)
                        TABLE 167 REST OF EUROPE: MARKET FOR CANCER, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 168 REST OF EUROPE: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 169 REST OF EUROPE: MARKET, BY END USER,  2021–2028 (USD MILLION)
             11.3.5 EUROPE: RECESSION IMPACT
     11.4 ASIA PACIFIC 
             TABLE 170 ASIA PACIFIC: EXOSOME RESEARCH MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 171 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
             TABLE 172 ASIA PACIFIC: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE,  2021–2028 (USD MILLION)
             TABLE 173 ASIA PACIFIC: MARKET, BY INDICATION,  2021–2028 (USD MILLION)
             TABLE 174 ASIA PACIFIC: MARKET FOR CANCER, BY TYPE,  2021–2028 (USD MILLION)
             TABLE 175 ASIA PACIFIC: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
             TABLE 176 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.1 CHINA
                        11.4.1.1 China to hold largest share in APAC market
                                      TABLE 177 CHINA: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 178 CHINA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 179 CHINA: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 180 CHINA: MARKET FOR CANCER, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 181 CHINA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 182 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.2 JAPAN
                        11.4.2.1 High cancer prevalence and increasing healthcare expenditure to drive market
                                      TABLE 183 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA, 2020 VS. 2022
                                      TABLE 184 JAPAN: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 185 JAPAN: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 186 JAPAN: MARKET, BY INDICATION, 2021–2028 (USD MILLION)
                                      TABLE 187 JAPAN: MARKET FOR CANCER, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 188 JAPAN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 189 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.3 REST OF ASIA PACIFIC
                        TABLE 190 REST OF ASIA PACIFIC: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                        TABLE 191 REST OF ASIA PACIFIC: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 192 REST OF ASIA PACIFIC: MARKET, BY INDICATION,  2021–2028 (USD MILLION)
                        TABLE 193 REST OF ASIA PACIFIC: MARKET FOR CANCER, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 194 REST OF ASIA PACIFIC: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 195 REST OF ASIA PACIFIC: MARKET, BY END USER,  2021–2028 (USD MILLION)
             11.4.4 ASIA PACIFIC: RECESSION IMPACT
     11.5 REST OF THE WORLD 
             TABLE 196 REST OF THE WORLD: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
             TABLE 197 REST OF THE WORLD: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE,  2021–2028 (USD MILLION)
             TABLE 198 REST OF THE WORLD: MARKET, BY INDICATION,  2021–2028 (USD MILLION)
             TABLE 199 REST OF THE WORLD: MARKET FOR CANCER, BY TYPE,  2021–2028 (USD MILLION)
             TABLE 200 REST OF THE WORLD: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
             TABLE 201 REST OF THE WORLD: MARKET, BY END USER,  2021–2028 (USD MILLION)
             11.5.1 REST OF THE WORLD: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE (Page No. - 182)
     12.1 OVERVIEW 
     12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
             FIGURE 30 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, 2020- 2023
     12.3 REVENUE ANALYSIS 
             FIGURE 31 REVENUE ANALYSIS OF TOP FIVE MARKET PLAYERS (2018–2022)
     12.4 MARKET SHARE ANALYSIS 
             TABLE 202 EXOSOME RESEARCH MARKET: DEGREE OF COMPETITION
     12.5 COMPANY EVALUATION MATRIX 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE
             12.5.4 EMERGING COMPANIES
                        FIGURE 33 EXOSOME RESEARCH INDUSTRY: COMPANY EVALUATION MATRIX, 2022
             12.5.5 COMPANY FOOTPRINT
                        TABLE 203 COMPANY FOOTPRINT (25 COMPANIES)
                        TABLE 204 PRODUCT & SERVICE FOOTPRINT (25 COMPANIES)
                        TABLE 205 GEOGRAPHIC FOOTPRINT (25 COMPANIES)
     12.6 START-UP/SME EVALUATION MATRIX 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 RESPONSIVE COMPANIES
             12.6.4 DYNAMIC COMPANIES
                        FIGURE 34 EXOSOME RESEARCH INDUSTRY: START-UP/SME EVALUATION MATRIX, 2022
             12.6.5 COMPETITIVE BENCHMARKING
                        TABLE 206 EXOSOME RESEARCH INDUSTRY: DETAILED LIST OF KEY START-UP/SME PLAYERS
                        TABLE 207 EXOSOME RESEARCH MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS [START-UPS/SMES]
     12.7 COMPETITIVE SCENARIO 
 
13 COMPANY PROFILES (Page No. - 196)
     13.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             13.1.1 THERMO FISHER SCIENTIFIC INC.
                        TABLE 208 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
                        FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
             13.1.2 QIAGEN
                        TABLE 209 QIAGEN: COMPANY OVERVIEW
                        FIGURE 36 QIAGEN: COMPANY SNAPSHOT (2022)
             13.1.3 LONZA
                        TABLE 210 LONZA: COMPANY OVERVIEW
                        FIGURE 37 LONZA: COMPANY SNAPSHOT (2022)
             13.1.4 SYSTEM BIOSCIENCES, LLC
                        TABLE 211 SYSTEM BIOSCIENCES, LLC: COMPANY OVERVIEW
             13.1.5 BIO-TECHNE
                        TABLE 212 BIO-TECHNE: COMPANY OVERVIEW
                        FIGURE 38 BIO-TECHNE: COMPANY SNAPSHOT (2022)
             13.1.6 DANAHER CORPORATION
                        TABLE 213 DANAHER CORPORATION: COMPANY OVERVIEW
                        FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.7 AMSBIO
                        TABLE 214 AMSBIO: COMPANY OVERVIEW
             13.1.8 ROOSTERBIO, INC.
                        TABLE 215 ROOSTERBIO, INC.: COMPANY OVERVIEW
             13.1.9 MILTENYI BIOTEC
                        TABLE 216 MILTENYI BIOTEC: COMPANY OVERVIEW
             13.1.10 NORGEN BIOTEK CORP.
                        TABLE 217 NORGEN BIOTEK CORP.: COMPANY OVERVIEW
     13.2 OTHER PLAYERS 
             13.2.1 AETHLON MEDICAL, INC.
             13.2.2 ANJARIUM BIOSCIENCES AG
             13.2.3 CILOA
             13.2.4 INNOVAPREP, LLC
             13.2.5 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC,
             13.2.6 ILIAS BIOLOGICS INC.
             13.2.7 UNCHAINED LABS
             13.2.8 RION INC.
             13.2.9 CELL GUIDANCE SYSTEMS LLC
             13.2.10 INOVIQ
             13.2.11 NX PHARMAGEN
             13.2.12 EXOPHARM
             13.2.13 EVERZOM
             13.2.14 NANOSOMIX
             13.2.15 CREATIVE BIOLABS
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
14 APPENDIX (Page No. - 231)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global exosome research market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the Exosome research market. The secondary sources used for this study include the Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), International Society for Extracellular Vesicles (ISEV), and UK Regenerative Medicine Platform (UKRMP), National Human Genome Research Institute (NHGRI), Asia Pacific Society of Human Genetics (APSHG), Genetics Society of America (GSA), European Society of Human Genetics (ESHG), Centers for Common Disease Genomics (CDDG), Center for Cellular and Molecular Biology (CCMB) (India). The Scientist Magazine, ScienceDirect, research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations, and others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global exosome research market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biopharmaceutical companies, CROs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across five major regions, including the Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Exosome Research Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the exosome research market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Bottom-up Approach

  • The key players in the industry and market have been identified through extensive secondary research.
  • The revenues generated from the exosome related business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Exosome Research Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Top-down Approach

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

Exosome Research Market Size, and Share

Data Triangulation

To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

In the process of data triangulation, we employed a multifaceted approach, incorporating primary data collection methods, analysis of the MarketsandMarkets (MnM) repository, and a comprehensive examination of company shares. By integrating insights from these diverse sources, we derived a meticulously validated and reliable estimate for the final market size.

Market Definition

Exosomes are biomembrane-like vesicles containing protein, miRNA, and lipids that can be delivered to the extracellular milieu (ECM). Exosomes are naturally produced within the body and could be utilized in cell-to-cell communication, molecular therapy for cancer treatment, and diagnosis of skeletal disorders. They have several advantages in cell-based treatment, which has brought attention to R&D in this field.

Stakeholders

  • Exosome research product manufacturers/contract research organizations (CROs)
  • Pharmaceutical and biopharmaceutical companies
  • Academic and research institutes
  • Venture capitalists and investors
  • Market research and consulting firms
  • Government associations
  • Medical institutions and universities

Report Objectives

  • To define, describe, segment, and forecast the exosome research market by product & service, indication, application, manufacturing service, end-user, and region
  • To provide detailed information about the major factors (drivers, restraints, opportunities, and challenges) influencing the market growth
  • To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall exosome research market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the exosome research market in five main regions: North America, Europe, Asia Pacific, Rest of the World, along with their respective key countries
  • To profile the key players in the exosome research market and comprehensively analyze their core competencies and market shares
  • To track and analyze competitive developments, such as product & service launches, acquisitions, expansions, collaborations, agreements, and partnerships of the leading players in the exosome research market
  • To benchmark players within the exosome research market using the ‘Competitive Leadership Mapping’ framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Portfolio Assessment

  • Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies.

Company Information

  • Detailed analysis and profiling of additional market players (up to three).

Geographical Analysis

  • A further breakdown of the Rest of the Asia Pacific exosome research market into other Rest of Asian countries
  • A further breakdown of the Rest of European exosome research market into other Rest of European countries
  • A further breakdown of the Rest of World exosome research market into other Rest of World countries
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
BT 6939
Published ON
Jan, 2024
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Exosome Research Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback